Zylox-Tonbridge Medical Technology Co Ltd
02190
Company Profile
Business description
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's products include Thrombite Clot Retriever Device (Thrombite CRD), Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB), and others. The company derives majority of its revenue from PRC.
Contact
270 Shuyun Road, Cangqian Street
Zylox-Tonbridge Industrial Park
Yuhang District, Zhejiang Province
Hangzhou
CHNT: +86 57188610082
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
925
Stocks News & Analysis
stocks
ASX share undervalued as margins expected to rebound
This ASX share remains overlooked despite a strong outlook.
stocks
Cheap retail REIT with an attractive yield
Lower consumer spending unlikely to buckle this retail REIT.
stocks
Expanding store network for ASX listed retailer
Sales growth but lack of margin expansion due to competition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,185.90 | 70.20 | 0.77% |
| CAC 40 | 8,476.45 | 29.18 | 0.35% |
| DAX 40 | 24,951.81 | 41.40 | 0.17% |
| Dow JONES (US) | 51,999.67 | 328.64 | 0.64% |
| FTSE 100 | 10,492.58 | 1.63 | -0.02% |
| HKSE | 24,312.16 | 181.79 | -0.74% |
| NASDAQ | 26,376.34 | 307.60 | -1.15% |
| Nikkei 225 | 69,902.25 | 497.75 | 0.72% |
| NZX 50 Index | 13,392.98 | 33.15 | -0.25% |
| S&P 500 | 7,511.35 | 42.94 | -0.57% |
| S&P/ASX 200 | 8,966.30 | 65.50 | 0.74% |
| SSE Composite Index | 4,108.08 | 16.18 | 0.40% |